Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bronchopulmonary PK of AT-527 in Healthy Subjects
NCT04877769Phase 1Completed
- Sponsor
- Atea Pharmaceuticals
- Start
- Apr 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bemnifosbuvir in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Atea Pharmaceuticals. Primary endpoint: Concentrations of AT-527 in epithelial lining fluid. Started Apr 2021; status: completed.
02
Drugs
bemnifosbuvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04877769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04877769.